Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Operations: 2017-2025

Historic Cash from Operations for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $9.7 million.

  • Puma Biotechnology's Cash from Operations fell 12.12% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.0 million, marking a year-over-year increase of 27.37%. This contributed to the annual value of $38.9 million for FY2024, which is 44.09% up from last year.
  • As of Q3 2025, Puma Biotechnology's Cash from Operations stood at $9.7 million, which was down 31.15% from $14.1 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Cash from Operations peaked at $17.3 million during Q3 2022, and registered a low of -$26.9 million during Q1 2022.
  • In the last 3 years, Puma Biotechnology's Cash from Operations had a median value of $10.5 million in 2023 and averaged $8.5 million.
  • Per our database at Business Quant, Puma Biotechnology's Cash from Operations plummeted by 18,648.65% in 2022 and then skyrocketed by 1,271.76% in 2025.
  • Puma Biotechnology's Cash from Operations (Quarterly) stood at -$5.4 million in 2021, then skyrocketed by 241.36% to $7.7 million in 2022, then skyrocketed by 36.08% to $10.5 million in 2023, then skyrocketed by 49.28% to $15.6 million in 2024, then dropped by 12.12% to $9.7 million in 2025.
  • Its last three reported values are $9.7 million in Q3 2025, $14.1 million for Q2 2025, and $3.6 million during Q1 2025.